Therapeutic Focus
Rodatristat Ethyl
Altavant’s lead candidate is rodatristat ethyl*, the prodrug of rodatristat, a tryptophan hydroxylase (TPH) inhibitor designed to block peripheral serotonin production. By lowering levels of serotonin in the circulation and in pulmonary tissues, rodatristat may represent a disease-modifying treatment for diseases characterized by pathological serotonin signaling. These diseases include pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF) and sarcoidosis.
*For ease of reading, this website sometimes uses the name “rodatristat” to refer to the prodrug rodatristat ethyl in addition to the active moiety.
Pipeline
| Compound | Disease | Phase |
|---|---|---|
| Rodatristat ethyl | Pulmonary Arterial Hypertension (PAH) | Phase 2 |
| Idiopathic Pulmonary Fibrosis (IPF) | Research | |
| Sarcoidosis | Research | |
| ALTA-2530 | Bronchiolitis Obliterans Syndrome | IND Enabling |
| Next-Generation TPH Inhibitors | Oral agents for multiple indications | Research |
| Alternative routes of administration for multiple indications | Research |
| Compound | Disease | Research | IND Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| Rodatristat Ethyl | Pulmonary Arterial Hypertension (PAH) | PAH STUDY NOW ENROLLING | ||||
| Idiopathic Pulmonary Fibrosis (IPF) | ||||||
| ALTA-2530 | Transplant-associated bronchiolitis obliterans syndrome | |||||
| Chemical-induced bronchiolitis obliterans syndrome | * Partnered with BARDA / NIAID | |||||
| Next-Generation TPH Inhibitors | Oral agents for multiple indications | |||||
| Alternative routes of administration of multiple indications | ||||||
